Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia

BACKGROUND: Sickle cell disease (SCD) is a severe and devastating hematological disorder that affects over 100,000 persons in the USA and millions worldwide. Hydroxyurea is the primary disease-modifying therapy for the SCD, with proven benefits to reduce both short-term and long-term complications....

Descripción completa

Detalles Bibliográficos
Autores principales: Meier, Emily R., Creary, Susan E., Heeney, Matthew M., Dong, Min, Appiah-Kubi, Abena O., Nelson, Stephen C., Niss, Omar, Piccone, Connie, Quarmyne, Maa-Ohui, Quinn, Charles T., Saving, Kay L., Scott, John P., Talati, Ravi, Latham, Teresa S., Pfeiffer, Amanda, Shook, Lisa M., Vinks, Alexander A., Lane, Adam, McGann, Patrick T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691962/
https://www.ncbi.nlm.nih.gov/pubmed/33246482
http://dx.doi.org/10.1186/s13063-020-04912-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691962/
https://www.ncbi.nlm.nih.gov/pubmed/33246482
http://dx.doi.org/10.1186/s13063-020-04912-z

Ejemplares similares